The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Neuromyelitis Optica Drug-Global Market Insights and Sales Trends 2025
Synopsis
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
The global Neuromyelitis Optica Drug market size is expected to reach US$ 58 million by 2029, growing at a CAGR of 3.0% from 2023 to 2029. The market is mainly driven by the significant applications of Neuromyelitis Optica Drug in various end use industries. The expanding demands from the Acute Attack and Remission Prophylactic Treatment, are propelling Neuromyelitis Optica Drug market. Glucocorticoids, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Immunotherapies segment is estimated at % CAGR for the next seven-year period.
Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.
The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Neuromyelitis Optica Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Neuromyelitis Optica Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Neuromyelitis Optica Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Neuromyelitis Optica Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Neuromyelitis Optica Drug covered in this report include Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork and Baxter, etc.
The global Neuromyelitis Optica Drug market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
Global Neuromyelitis Optica Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Neuromyelitis Optica Drug market, Segment by Type:
Glucocorticoids
Immunotherapies
Others
Global Neuromyelitis Optica Drug market, by Application
Acute Attack
Remission Prophylactic Treatment
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Neuromyelitis Optica Drug companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
The global Neuromyelitis Optica Drug market size is expected to reach US$ 58 million by 2029, growing at a CAGR of 3.0% from 2023 to 2029. The market is mainly driven by the significant applications of Neuromyelitis Optica Drug in various end use industries. The expanding demands from the Acute Attack and Remission Prophylactic Treatment, are propelling Neuromyelitis Optica Drug market. Glucocorticoids, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Immunotherapies segment is estimated at % CAGR for the next seven-year period.
Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.
The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Neuromyelitis Optica Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Neuromyelitis Optica Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Neuromyelitis Optica Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Neuromyelitis Optica Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Neuromyelitis Optica Drug covered in this report include Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork and Baxter, etc.
The global Neuromyelitis Optica Drug market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
Global Neuromyelitis Optica Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Neuromyelitis Optica Drug market, Segment by Type:
Glucocorticoids
Immunotherapies
Others
Global Neuromyelitis Optica Drug market, by Application
Acute Attack
Remission Prophylactic Treatment
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Neuromyelitis Optica Drug companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Neuromyelitis Optica Drug
1.1 Neuromyelitis Optica Drug Market Overview
1.1.1 Neuromyelitis Optica Drug Product Scope
1.1.2 Neuromyelitis Optica Drug Market Status and Outlook
1.2 Global Neuromyelitis Optica Drug Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Neuromyelitis Optica Drug Market Size by Region (2018-2029)
1.4 Global Neuromyelitis Optica Drug Historic Market Size by Region (2018-2023)
1.5 Global Neuromyelitis Optica Drug Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Neuromyelitis Optica Drug Market Size (2018-2029)
1.6.1 North America Neuromyelitis Optica Drug Market Size (2018-2029)
1.6.2 Europe Neuromyelitis Optica Drug Market Size (2018-2029)
1.6.3 Asia-Pacific Neuromyelitis Optica Drug Market Size (2018-2029)
1.6.4 Latin America Neuromyelitis Optica Drug Market Size (2018-2029)
1.6.5 Middle East & Africa Neuromyelitis Optica Drug Market Size (2018-2029)
2 Neuromyelitis Optica Drug Market by Type
2.1 Introduction
2.1.1 Glucocorticoids
2.1.2 Immunotherapies
2.1.3 Others
2.2 Global Neuromyelitis Optica Drug Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Neuromyelitis Optica Drug Historic Market Size by Type (2018-2023)
2.2.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Neuromyelitis Optica Drug Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Neuromyelitis Optica Drug Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Neuromyelitis Optica Drug Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Neuromyelitis Optica Drug Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Neuromyelitis Optica Drug Revenue Breakdown by Type (2018-2029)
3 Neuromyelitis Optica Drug Market Overview by Application
3.1 Introduction
3.1.1 Acute Attack
3.1.2 Remission Prophylactic Treatment
3.2 Global Neuromyelitis Optica Drug Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Neuromyelitis Optica Drug Historic Market Size by Application (2018-2023)
3.2.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Neuromyelitis Optica Drug Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Neuromyelitis Optica Drug Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Neuromyelitis Optica Drug Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Neuromyelitis Optica Drug Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Neuromyelitis Optica Drug Revenue Breakdown by Application (2018-2029)
4 Neuromyelitis Optica Drug Competition Analysis by Players
4.1 Global Neuromyelitis Optica Drug Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2022)
4.3 Date of Key Players Enter into Neuromyelitis Optica Drug Market
4.4 Global Top Players Neuromyelitis Optica Drug Headquarters and Area Served
4.5 Key Players Neuromyelitis Optica Drug Product Solution and Service
4.6 Competitive Status
4.6.1 Neuromyelitis Optica Drug Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Neuromyelitis Optica Drug Products, Services and Solutions
5.1.4 Pfizer Neuromyelitis Optica Drug Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Fresenius
5.2.1 Fresenius Profile
5.2.2 Fresenius Main Business
5.2.3 Fresenius Neuromyelitis Optica Drug Products, Services and Solutions
5.2.4 Fresenius Neuromyelitis Optica Drug Revenue (US$ Million) & (2018-2023)
5.2.5 Fresenius Recent Developments
5.3 Teva
5.3.1 Teva Profile
5.3.2 Teva Main Business
5.3.3 Teva Neuromyelitis Optica Drug Products, Services and Solutions
5.3.4 Teva Neuromyelitis Optica Drug Revenue (US$ Million) & (2018-2023)
5.3.5 Sandoz Recent Developments
5.4 Sandoz
5.4.1 Sandoz Profile
5.4.2 Sandoz Main Business
5.4.3 Sandoz Neuromyelitis Optica Drug Products, Services and Solutions
5.4.4 Sandoz Neuromyelitis Optica Drug Revenue (US$ Million) & (2018-2023)
5.4.5 Sandoz Recent Developments
5.5 Intas
5.5.1 Intas Profile
5.5.2 Intas Main Business
5.5.3 Intas Neuromyelitis Optica Drug Products, Services and Solutions
5.5.4 Intas Neuromyelitis Optica Drug Revenue (US$ Million) & (2018-2023)
5.5.5 Intas Recent Developments
5.6 Gyjtrs
5.6.1 Gyjtrs Profile
5.6.2 Gyjtrs Main Business
5.6.3 Gyjtrs Neuromyelitis Optica Drug Products, Services and Solutions
5.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue (US$ Million) & (2018-2023)
5.6.5 Gyjtrs Recent Developments
5.7 NANG KUANG
5.7.1 NANG KUANG Profile
5.7.2 NANG KUANG Main Business
5.7.3 NANG KUANG Neuromyelitis Optica Drug Products, Services and Solutions
5.7.4 NANG KUANG Neuromyelitis Optica Drug Revenue (US$ Million) & (2018-2023)
5.7.5 NANG KUANG Recent Developments
5.8 Tianjin Kingyork
5.8.1 Tianjin Kingyork Profile
5.8.2 Tianjin Kingyork Main Business
5.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Products, Services and Solutions
5.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue (US$ Million) & (2018-2023)
5.8.5 Tianjin Kingyork Recent Developments
5.9 Baxter
5.9.1 Baxter Profile
5.9.2 Baxter Main Business
5.9.3 Baxter Neuromyelitis Optica Drug Products, Services and Solutions
5.9.4 Baxter Neuromyelitis Optica Drug Revenue (US$ Million) & (2018-2023)
5.9.5 Baxter Recent Developments
5.10 CSL
5.10.1 CSL Profile
5.10.2 CSL Main Business
5.10.3 CSL Neuromyelitis Optica Drug Products, Services and Solutions
5.10.4 CSL Neuromyelitis Optica Drug Revenue (US$ Million) & (2018-2023)
5.10.5 CSL Recent Developments
5.11 Grifols
5.11.1 Grifols Profile
5.11.2 Grifols Main Business
5.11.3 Grifols Neuromyelitis Optica Drug Products, Services and Solutions
5.11.4 Grifols Neuromyelitis Optica Drug Revenue (US$ Million) & (2018-2023)
5.11.5 Grifols Recent Developments
5.12 Octapharma
5.12.1 Octapharma Profile
5.12.2 Octapharma Main Business
5.12.3 Octapharma Neuromyelitis Optica Drug Products, Services and Solutions
5.12.4 Octapharma Neuromyelitis Optica Drug Revenue (US$ Million) & (2018-2023)
5.12.5 Octapharma Recent Developments
5.13 CBOP
5.13.1 CBOP Profile
5.13.2 CBOP Main Business
5.13.3 CBOP Neuromyelitis Optica Drug Products, Services and Solutions
5.13.4 CBOP Neuromyelitis Optica Drug Revenue (US$ Million) & (2018-2023)
5.13.5 CBOP Recent Developments
6 North America
6.1 North America Neuromyelitis Optica Drug Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Neuromyelitis Optica Drug Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Neuromyelitis Optica Drug Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Neuromyelitis Optica Drug Market Dynamics
11.1 Neuromyelitis Optica Drug Industry Trends
11.2 Neuromyelitis Optica Drug Market Drivers
11.3 Neuromyelitis Optica Drug Market Challenges
11.4 Neuromyelitis Optica Drug Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
